Peters Dominik, Radine Claudia, Reese Alina, Budach Wilfried, Sohn Dennis, Jänicke Reiner U
Laboratory of Molecular Radiooncology, Clinic for Radiation Therapy and Radiooncology, Medical Faculty of the Heinrich Heine University, 40255 Düsseldorf, Germany.
Laboratory of Molecular Radiooncology, Clinic for Radiation Therapy and Radiooncology, Medical Faculty of the Heinrich Heine University, 40255 Düsseldorf, Germany.
J Biol Chem. 2017 May 19;292(20):8331-8341. doi: 10.1074/jbc.M116.772327. Epub 2017 Mar 27.
The cyclin-dependent kinase inhibitor p21 is an important player in stress pathways exhibiting both tumor-suppressive and oncogenic functions. Thus, expression of p21 has to be tightly controlled, which is achieved by numerous mechanisms at the transcriptional, translational, and posttranslational level. Performing immunoprecipitation of bromouridine-labeled p21 mRNAs that had been incubated before with cytoplasmic extracts of untreated HCT116 colon carcinoma cells, we identified the DEAD-box RNA helicase DDX41 as a novel regulator of p21 expression. DDX41 specifically precipitates with the 3'UTR, but not with the 5'UTR, of p21 mRNA. Knockdown of DDX41 increases basal and γ irradiation-induced p21 protein levels without affecting p21 mRNA expression. Conversely, overexpression of DDX41 strongly inhibits expression of a FLAG-p21 and a luciferase construct, but only in the presence of the p21 3'UTR. Together, these data suggest that this helicase regulates p21 expression at the translational level independent of the transcriptional activity of p53. However, knockdown of DDX41 completely fails to increase p21 protein levels in p53-deficient HCT116 cells. Moreover, posttranslational up-regulation of p21 achieved in both p53 and p53 HCT116 cells in response to pharmaceutical inhibition of the proteasome (by MG-132) or p90 ribosomal S6 kinases (by BI-D1870) is further increased by knockdown of DDX41 only in p53-proficient but not in p53-deficient cells. Although our data demonstrate that DDX41 suppresses p21 translation without disturbing the function of p53 to directly induce p21 mRNA expression, this process indirectly requires p53, perhaps in the form of another p53 target gene or as a still undefined posttranscriptional function of p53.
细胞周期蛋白依赖性激酶抑制剂p21是应激途径中的重要因子,兼具肿瘤抑制和致癌功能。因此,p21的表达必须受到严格调控,这在转录、翻译和翻译后水平通过多种机制得以实现。我们对用溴尿苷标记的p21 mRNA进行免疫沉淀,这些mRNA之前已与未处理的HCT116结肠癌细胞的细胞质提取物孵育,结果鉴定出DEAD盒RNA解旋酶DDX41是p21表达的新型调节因子。DDX41特异性地与p21 mRNA的3'非翻译区(UTR)共沉淀,而不与5'UTR共沉淀。敲低DDX41可增加基础水平和γ射线照射诱导的p21蛋白水平,而不影响p21 mRNA的表达。相反,DDX41的过表达强烈抑制FLAG-p21和荧光素酶构建体的表达,但仅在存在p21 3'UTR的情况下。总之,这些数据表明,这种解旋酶在翻译水平调节p21的表达,独立于p53的转录活性。然而,在p53缺陷的HCT116细胞中敲低DDX41完全无法增加p21蛋白水平。此外,在p53野生型和p53缺失的HCT116细胞中,通过蛋白酶体抑制剂(MG-132)或p90核糖体S6激酶抑制剂(BI-D1870)药物抑制实现的p21翻译后上调,仅在p53野生型细胞中敲低DDX41时进一步增加,而在p53缺陷细胞中则不然。尽管我们的数据表明DDX41抑制p21的翻译而不干扰p53直接诱导p21 mRNA表达的功能,但这一过程间接需要p53,可能是以另一个p53靶基因的形式,或者是作为p53尚未明确的转录后功能。